Last updated: July 28, 2026
Omnipaque 240 (iohexol 240 mgI/mL) is an established low-osmolar iodinated contrast agent with a mature, largely generic market; a defensible “clinical trials pipeline update” is not available in the open record as a single, discrete, product-specific development program tied to Omnipaque 240 alone. Market and projection analysis therefore depends on (1) the overall iodinated contrast media (ICM) market trajectory, (2) competitive intensity from iohexol generics and multi-source ICMs, and (3) procurement dynamics for hospitals and imaging networks rather than identifiable late-stage Omnipaque-only clinical milestones.
Omnipaque 240 (iohexol 240 mgI/mL) clinical trials update: What ongoing studies exist and what do they target?
Are there Omnipaque 240–specific late-stage trials (Phase 3/registration) vs class trials?
No public, product-anchored Phase 3 or registration-level Omnipaque 240 clinical program is reliably identifiable from standard regulatory and clinical-trials sources as a standalone development track. The dominant pattern for Omnipaque 240 in the modern era is:
- New clinical evidence tends to be generated for the broader iodinated contrast class (ICM) or for specific use-technique combinations (dose, injection protocol, imaging modality).
- Product-level updates typically occur via label changes, formulation/manufacturing adjustments, or supplemental indications rather than new pivotal trials under the Omnipaque 240 label.
What trial topics are typically studied for iohexol 240 in current practice?
Where new clinical literature emerges for iohexol-containing ICMs, it usually concerns one or more of the following high-frequency decision points for hospitals:
- Contrast dose optimization (reduced dose CT angiography or CT in specific cohorts)
- Injection rate and volume protocols (automated injectors, bolus timing)
- Comparative performance in select imaging settings (CT, CTA, urography)
- Safety endpoints in at-risk populations (renal impairment, prior reactions)
- Protocol compliance and workflow endpoints (e.g., contrast administration procedures)
What do clinical trial “updates” look like when the active is iohexol but the product is multisource?
For multisource small molecules like iohexol, clinical activity is often not “Omnipaque 240 only,” but rather:
- Shared active ingredient evidence across brands
- Trials designed around modality, dosing, or administration technique rather than brand-specific chemistry
In practice, this means the most actionable “clinical trials update” for Omnipaque 240 stakeholders is less about finding a distinct Phase 3 program and more about tracking:
- Labeling/label expansion signals from FDA (safety communications, administration guidance, renal impairment language)
- Uptake of protocols that change dose and timing patterns (which affects unit consumption)
What is the latest regulatory “clinical” signal for iohexol ICMs relevant to Omnipaque 240?
No discrete Omnipaque 240-only regulatory milestone can be treated as the primary “clinical update” in the public record. The operative clinical signal is class-level safety and administration guidance, which affects ordering behavior (e.g., renal monitoring workflows, reaction preparedness), not a brand-specific trial program.
Omnipaque 240 market analysis: How big is the iodinated contrast market and where does Omnipaque 240 fit?
What is the addressable market Omnipaque 240 competes in?
Omnipaque 240 competes in iodinated contrast media (ICM) used across:
- CT (including routine and advanced body CT)
- CTA (cardiac and vascular imaging)
- Urography and related imaging where low-osmolar ICMs are used
- Other radiology workflows where iohexol is chosen based on tolerability, protocol compatibility, and hospital purchasing
Omnipaque 240’s unit demand is driven by imaging volume (CT/CTA utilization) and by hospital formularies that prefer certain ICM SKUs based on:
- Price and contract pricing
- Stocking and distribution reliability
- Substitution rules between iodinated contrast agents
- Standardization of injection protocols (which reduces training and protocol deviation)
What competitive set pressures Omnipaque 240?
Omnipaque 240 is not protected as a unique, premium single-source product in the modern purchasing environment. Key competitive pressures include:
- Generic iohexol 240 mgI/mL products (multi-source)
- Other low-osmolar iodinated contrasts (therapeutic category substitution)
- Larger institutional contracting that may swap brands within equivalent clinical protocols
What matters more for Omnipaque 240 pricing than innovation?
Price and contract dynamics dominate:
- GPO and IDN formulary negotiations
- Competitive tendering at the SKU level
- Standard contract volumes where switching costs exist, but cost pressure still drives substitution
Omnipaque 240 market projections: What unit and revenue trajectory is most likely?
What is the base case trajectory for Omnipaque 240 in a mature multisource ICM market?
In a mature multisource setting, projections typically show:
- Volume stability to modest growth aligned with overall CT utilization
- Revenue per unit decline or flat-to-down pricing driven by generic competition
- Periodic share shifts based on contract awards rather than clinical superiority claims
What growth levers could expand Omnipaque 240 consumption?
Potential levers include:
- Continued expansion of CT/CTA throughput in hospitals and outpatient imaging centers
- Protocol standardization favoring low-osmolar agents in certain pathways
- Population aging increasing imaging frequency
- Adoption of contrast-enhanced imaging where iohexol fits established injection protocols
What headwinds could reduce Omnipaque 240 consumption or speed substitution?
- Aggressive tendering by large health systems
- Switch to alternative ICMs due to acquisition cost
- Dose optimization protocols that reduce total mL per scan
- Safety-driven pathway changes that alter preferred agent selection in high-risk cohorts
How does Omnipaque 240 compare with other iodinated contrasts and with alternative iohexol SKUs?
Omnipaque 240 vs other iohexol concentrations: What swaps occur in formularies?
Within iohexol-containing ICM portfolios, hospitals often standardize around a concentration and injection protocol. If dosing protocols change or if contract incentives favor another strength, substitution can occur, affecting Omnipaque 240 specifically.
Omnipaque 240 vs non-iohexol low-osmolar ICMs: What is the decision logic?
Hospitals typically evaluate:
- Relative tolerability profile and adverse event history in their internal experience
- Protocol compatibility with injector pumps and imaging protocols
- Contract pricing and supply reliability
- Clinician familiarity and institutional pathways
What is the Orange Book status of Omnipaque 240 and what does that imply for exclusivity?
Is Omnipaque 240 still under meaningful new-drug exclusivity?
Given the age of iohexol and the extensive multisource landscape for iodinated contrasts, Omnipaque 240 is best characterized as outside meaningful new-drug exclusivity in the near term. The operative market constraint for “future generic entry” is less about exclusivity expiry and more about:
- Continuation of generic supply in the specific SKU format
- Whether any remaining patent thickets exist for formulation, packaging, or method-of-use tied to specific dosing protocols
How do method-of-use and formulation patents affect Omnipaque 240 market access?
Any lingering patent protections, if present, usually address incremental properties:
- Packaging or container systems
- Stability and manufacturing methods
- Specific clinical claims or protocols
In practice for ICM purchasing, clinicians rarely select based on patent coverage. Purchasers select based on contract economics, supply, and protocol fit.
What generic entry risks exist for Omnipaque 240 and how quickly would they matter?
Where do new entrants still find “open space” in ICM?
Even in a mature market, entry can occur via:
- New generic manufacturers securing contracts
- Supply-chain expansions that allow better pricing into IDNs
- Variant presentations (specific pack sizes, carton configurations) that change tender competitiveness
What are the commercial timing realities?
For a commodity-like ICM SKU:
- Tender cycles drive adoption timing more than launch marketing
- Competitive pricing pressure shows up quickly after contract awards
- Switching can be slow where protocols require retraining, but that friction is usually manageable in radiology departments
What patent litigation affects Omnipaque 240?
Is there active Omnipaque 240 patent litigation driving market impact?
No consistently identifiable, product-specific litigation record can be treated as a driver for Omnipaque 240 market impact in the public domain at a level suitable for direct business decision-making.
For iodinated contrasts, litigation signals that matter commercially typically involve:
- High-stakes formulation or packaging patents
- Settlements affecting specific presentations or strengths
FDA pathway and regulatory status: What approvals define Omnipaque 240 today?
What FDA status applies to Omnipaque 240?
Omnipaque 240 is an FDA-approved iodinated contrast product used in clinical imaging. For market dynamics, the key practical regulatory reality is that:
- Multiple approved alternatives exist through generic pathways and/or alternative ICM approvals
- Procurement relies on local formulary and contract decisions, not on single-product regulatory scarcity
What changes in FDA labeling tend to affect utilization most?
Labeling changes that influence utilization usually involve:
- Safety monitoring language (e.g., renal impairment risk workflows)
- Management of hypersensitivity reactions
- Administration precautions and contraindications
Key market deal dynamics: How do hospitals typically procure Omnipaque 240?
What drives market share between competing ICM SKUs?
Procurement typically follows:
- Contract pricing and rebate structures through GPO/IDN channels
- Supply assurance and lead times
- Clinical pathway fit (order sets and radiology protocols)
- Standard stock management (single SKU simplifies inventory controls)
Key Takeaways
- Omnipaque 240 is a mature iodinated contrast agent (iohexol 240 mgI/mL) operating in a multi-source environment where identifiable brand-specific late-stage clinical development is not the primary market variable.
- Market trajectory is mainly governed by CT/CTA utilization, procurement contracting, and dose/protocol standardization that can change total mL consumption per study.
- Future “clinical updates” for stakeholders are more likely to be label/safety workflow signals and protocol evidence than new pivotal Omnipaque 240 trials.
- Commercial risk is dominated by continued generic and category substitution through tender cycles rather than by a single remaining exclusivity wall.
FAQs
- How does dose optimization in CT change Omnipaque 240 volume demand?
- What hospital formularies decide between iohexol 240 and other low-osmolar iodinated contrast agents?
- How do GPO and IDN contract tender cycles typically shift market share for ICM SKUs like Omnipaque 240?
- Do renal impairment protocols influence which iodinated contrast agents are preferred for CTA or CT body imaging?
- What packaging size and carton presentation factors affect switching and adoption speed for Omnipaque 240 generics?
References (APA)
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
- U.S. FDA. (n.d.). FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process
